Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Council Backs Public Knowledge-Based Application for Additional Indication for Novartis’ Sandostatin
February 14, 2020
- Enhertu, BNCT, Tepotinib and More Up for MHLW Panel Review; March Approval Eyed
February 13, 2020
- MHLW Calls for Stable Supplies of HIV Drugs amid Coronavirus Outbreak
February 13, 2020
- PMDA to Set Up New Consultation Services for Continuous Manufacturing, Database Use
February 12, 2020
- MHLW Urges Pharmacies to Limit Per-Customer Purchases for Face Masks, Sanitizer
February 12, 2020
- Chuikyo Issues Recommendation for 2020 Reimbursement Reform; Biosimilar Premium Set at 1,500 Yen per Month
February 10, 2020
- Chuikyo OKs Supplementary Opinions for 2020 Reimbursement Reform; No Mention on Health Coverage Review
February 6, 2020
- AMED to Share Research Data to Tackle Wuhan Coronavirus
February 4, 2020
- Chuikyo’s Draft Supplementary Opinions for 2020 Reimbursement Reform Calls for Medical Validity, Cost-Effective Analysis for Prescriptions
February 3, 2020
- Takeda’s RCC Drug Cabometyx Now in Line for March Approval; Alecensa, Rozlytrek Opdivo and More
January 30, 2020
- MHLW to Incentivize Physicians to Use Biosimilars with New Premium
January 30, 2020
- Sanofi to Temporarily Stop Taking Orders for ActHIB due to “Multiple Cases” of Rust Found in Needles: MHLW
January 30, 2020
- Japan Ups Responses against Wuhan Coronavirus as First Domestic Transmission Confirmed
January 29, 2020
- MHLW Panel Gives Thumbs Up for Novartis’ ADM Med Brolucizumab for Approval in as Early as March
January 29, 2020
- Discussions on Off-Year Re-Pricing to Begin in Spring, Focus on Scope of Drugs, Impact on Stakeholders: MHLW Bureau Chief
January 27, 2020
- ICH’s Guidelines Helped Bring NDMA Contamination Problem to Light: NIHS Officials
January 24, 2020
- Japan Approved World’s 1st Topical JAK Inhibitor Delgocitinib, and More
January 24, 2020
- PMDA to Provide Information Free of Charge for Drug Makers to Consider Use of MID-NET Starting in April
January 24, 2020
- Chuikyo OKs New Drug Pricing Rules for 2020 Reform
January 23, 2020
- Nasal Steroid Used as “Reference Drug” for Xolair in Special Re-Pricing
January 23, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…